The present invention aims at providing a vaccine composition capable of being administered to an intraoral
mucous membrane, ocular
mucous membrane, ear
mucous membrane, genital mucous membrane, pharyngeal mucous membrane,
respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane,
gastric mucous membrane, enteric mucous membrane, or rectal mucous membrane, that is safe, useful as a prophylactic or therapeutic agent for infectious diseases or cancers, and capable of effectively inducing the systemic immune response and mucosal immune response. The present invention provides a
mucosal vaccine composition to be administered to at least one mucous membrane selected from the group consisting of a human or animal intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane,
respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane,
gastric mucous membrane, enteric mucous membrane, and rectal mucous membrane, the
mucosal vaccine composition containing: at least one
antigen; and as an
adjuvant, a
lipopolysaccharide derived from at least one
gram-negative bacterium selected from the group consisting of
Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus,
Gluconacetobacter,
Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia,
Pseudomonas,
Achromobacter, Bacillus, Methanoculleus, Methanosarcina,
Clostridium,
Micrococcus,
Flavobacterium,
Pantoea,
Acetobacter,
Zymomonas,
Xanthomonas, and
Enterobacter, or a salt thereof, wherein a
mass ratio between the
adjuvant and the
antigen (total
mass of the
adjuvant / total
mass of the
antigen) is 0.002 to 500.